CCL2 and Other metabolic disease: Reciprocally, reduced hepatic steatosis in obese mice deficient in the CCR2 receptor was observed [31]; (4) inhibition of CCR2 could improve diet-induced obesity and related metabolic disorders, such as insulin resistance and hepatic steatosis, by suppressing inflammation in adipose tissue [32]; (5) hyperhomocysteinemia is a metabolic disorder associated with liver injury and chronic inflammation through induction of CCL2 production in the liver [33].